Summary of meta-analyses of studies involving TIRADS classifications (EU-TIRADS, ACR-TIRADS, and K-TIRADS) in evaluating the malignant potential of focal lesions of the thyroid gland

Ultrasonography (USG) is a non-invasive and widely available diagnostic tool in the evaluation of focal thyroid lesions. The main limitation associated with the modality is the subjectivity of assessment of ultrasound features and the fact that it is impossible to visualise structures located retrosternally⁽¹⁾. It is characterised by relatively low diagnostic sensitivity for particular ultrasound features in estimating the malignant potential of focal lesions (27–63%), with high specificity reported for features including microcalcifications (87.8%), central vascularisation (78%), irregular margins (83.2%), shape higher than wider (96%), use of elastography (86.2%)⁽²⁾. In 2009, Horvath et al., based on the Breast Imaging Reporting and Data System (BIRADS), was the first to propose a similar classification for thyroid imaging – Thyroid Imaging Reporting and Data System (TIRADS). The aim was to introduce a lexicon of sonographic features of focal thyroid lesions, to categorize findings, and to define further diagnostic and therapeutic management, including indications for fine-needle aspiration biopsy (FNAB)⁽³⁾. Targeted fine-needle aspiration biopsy is an important diagnostic tool for focal thyroid lesions, thus being a necessary complement to ultrasound diagnosis. Over the following years, numerous scientific societies worldwide have published classifications estimating the risk of focal thyroid lesions and presenting varied size thresholds and ultrasound features for each category, including those for biopsy.

The TIRADS classification is intended to have a high sensitivity and thus exclude low-risk lesions from biopsy and minimise the proportion of false-negative lesions. However, it should be noted that in addition to sensitivity, it is important to obtain the highest possible level of specificity, in order to eliminate over-diagnosing and treating patients who do not actually need it. Unfortunately, there is no perfect tool with sensitivity and specificity levels equal to 100%, so it is essential to compare different classifications and adapt the best one to the diagnostic needs in a given population.

In this publication, the authors present a review of the literature based on meta-analyses on the most frequently cited TIRADS classifications.

The EU-TIRADS classification was introduced in 2017 and presented as a guideline by the European Thyroid Association (ETA)⁽⁴⁾. This scoring system is derived from the French classification, which was prospectively validated before its introduction, and its high diagnostic value was confirmed by Yoon et al. in a study of 4,696 thyroid nodules (TN), which showed a high level of sensitivity and negative predictive value (NPV)⁽⁵⁾. The lesions were divided into four categories – from 2 to 5 (EU-TIRADS 1 corresponds to the normal thyroid). A description of each category, tumour risk, and suggested indications for biopsy are shown in Tab. 1. A description of the lesions from each category is accompanied by sample ultrasound images (Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5, Fig. 6).

Fig. 1

Fig. 3

Fig. 5

Fig. 2

Fig. 4

Fig. 6

The actual performance of the EU-TIRADS classification has also been tested on the Polish population. It was first

evaluated by Skowrońska et al. on a group of 52 patients with the presence of 40 TNs; the evaluation of the nature of the lesions was performed in relation to the histopathological examination⁽⁶⁾. The percentage of thyroid cancer was 0% in EU-TIRADS 2; 0% in EU-TIRADS 3; 5.9% in EU-TIRADS 4, and 75% in EU-TIRADS 5. When EU-TIRADS ≥4 was used as the cut-off value, the sensitivity, specificity, PPV (positive predictive value) and NPV were 75%, 94.1%, 75% and 94.1%, respectively.

Another study conducted to verify the diagnostic efficacy of the EU-TIRADS RSS (Risk Stratification Scale) in the Polish setting was a multi-centre study published by Dobruch-Sobczak et al., in which a total of 842 TNs (613 benign, 229 malignant) were identified in 428 patients, and their nature was confirmed by histopathological verification⁽⁷⁾. The malignancy rate per EU-TIRADS category was as follows: 0% (EU-TIRADS 2), 3.2% (EU-TIRADS 3), 11.7% (EU-TIR ADS 4), and 43.5% (EU-TIR ADS 5). The authors showed that if the cut-off points for FNAB proposed in the guidelines were used, 36% of malignant TNs would be missed. The cut-off value at EU-TIRADS 4 was characterised by high sensitivity (100%) an low specificity (25.1%); at the cut-off for EU-TIRADS 5 the values were 93.4% and 54.6%, respectively. Another study seeking to evaluate the benefits of the EU-TIRADS classification in the Polish population was the prospective study by Szczepanek-Parulska et al. in which a total of 133 TNs from 88 patients were analysed, bringing the following results: sensitivity 90.9%, specificity 61.2%, PPV 69.8%, NPV 87.2%, and accuracy 75.9%⁽⁸⁾. Another study conducted in Poland assessed the usefulness of the EU-TIRADS classification in the diagnosis of TNs from Hürthle cells (HC) with ambiguous cytological findings. The aim of the study was to compare the diagnostic efficacy of EU-TIRADS in two groups of TNs with equivocal cytology (categories III–V of the Bethesda system), with and without Hürthle cells. The study included a total of 162 HC and 378 non-HC TNs with an established histopathological diagnosis (17.9% and 15.6% of tumours). The authors concluded that the EU-TIRADS classification did not support clinical decision-making in patients with cytologically equivocal HC TNs, especially those classified as category IV of the Bethesda System for Reporting Thyroid Cytopathology (BSRTC)⁽⁹⁾. The EU-TIRADS score was also found to correlate with a positive BRAF mutation in patients with early-stage papillary thyroid carcinoma (PTC). However, since the conclusions were drawn based on the analysis of just 49 lesions, they need to be confirmed in large-scale studies⁽¹⁰⁾.

A recently published paper including 80 patients supported the idea of active surveillance of TN <1 cm classified as EU-TIRADS 5⁽¹¹⁾. Sixteen (20.0%) of these patients underwent surgery after a median follow-up of 57.2 months, which confirmed the diagnosis of PTC in 15 out of 16 cases, and all were in remission after a follow-up of 6–12 months. The results suggest good accuracy of the EU-TIRADS 5 category in the classification of malignant TNs even <1 cm in diameter, and the possibility of careful monitoring for TNs classified as EU-TIRADS 5⁽¹¹⁾.

The largest published multi-centre study undertaken to date with a view to evaluating the diagnostic performance of EU-TIRADS with respect to histopathology was that conducted by Trimboli et al.⁽¹²⁾. This retrospective study included a total of 1,058 TNs, of which 24.3% proved to be malignant. The incidence of malignancy was 1.4%, 3.5%, 17%, and 87.7% in grades 2–5. When EU-TIRADS categories 4 and 5 were combined, 93% sensitivity and 97% NPV were achieved. Using the recommended criteria for FNAB, a decrease in NPV to 90.9% was achieved. The largest meta-analysis on this topic was published by Castellana et al.⁽¹³⁾ Seven studies evaluating a total of 5,672 TNs with histopathological evaluation as the reference standard were included. The incidence of malignancy in each EU-TIRADS category was: 0.5%, 5.9%, 21.4%, and 76.1%. The sensitivity, specificity, PPV, NPV of EU-TIRADS 5 were 83.5%, 84.3%, 76.1%, and 85.4%, respectively. Further improvement in results was found after excluding two studies with limited sample size and low incidence of malignancies in class 5⁽¹³⁾. The efficacy of the EU-TIRADS score was also tested in a paediatric population of 24 patients (31 TNs), 14 of whom underwent thyroidectomy; all malignant TNs were classified as EU-TIRADS grade 4 or 5. The sensitivity of the EU-TIRADS classification in detecting malignant TNs was 100%, specificity was 25%, PPV was 44%, and NPV was 100%⁽¹⁴⁾.

One recent study by Kovatcheva et al. aimed to evaluate the utility of the EU-TIRADS score in the assessment of TNs for FNAB and its ability to reduce unnecessary FNABs⁽¹⁵⁾. The study was a prospective single-centre analysis and included 741 patients with a total of 942 TNs. The malignancy rates in the categories 2 to 5 were 0, 0, 3.8, and 30.6%, respectively. The sensitivity, specificity, PPV, NPV and accuracy of EU-TIRADS with a cut-off point in category 5 were 91.3, 74.6, 30.6, 98.6, and 76.4%, respectively. The diagnostic performance in aspects other than sensitivity and NPV was better in nodules ≥10 mm in size. The authors noted that the number of FNABs would decrease by 53.4% if the FNAB criteria were strictly followed. When FNAB indications were followed, the estimated sensitivity, specificity, PPV and NPV of EU-TIRADS were 69.9, 56.3, 16.4 and 93.8%, respectively⁽¹⁵⁾. The usefulness of EU-TIRADS was also demonstrated in a group of 75 TNs showing increased radioisotope uptake on 18F-FDG PET/CT, which was further evaluated on thyroid ultrasound. The cancer rate in this group was 0% in EU-TIRADS 2, 2.9% in EU-TIRADS 3, 4.2% in EU-TIR ADS 4 and 78.6% in EU-TIR ADS 5 (p <0.001). The sensitivity, specificity, PPV, NPV and scale accuracy were found to be 5%, 95%, 79%, 97% and 93%, respectively. Based on these findings, it was concluded that EU-TIRADS might be helpful in predicting the nature of TNs detected by 18F-FDG PET/CT⁽¹⁶⁾.

In conclusion, the EU-TIRADS system is a simple and valuable RSS with a very good level of sensitivity, easy to incorporate into clinical practice. Its main strength lies in very high NPV, which contributes to reducing the number of FNABs.

In 2017, the American College of Radiology (ACR), in collaboration with the American Association of Clinical Endocrinologists (AAEC) and the American Thyroid Association (ATA), developed a practical ultrasound system for assessing the malignancy risk of thyroid nodules, called the ACR Thyroid Imaging, Reporting and Data System (ACR-TIRADS)⁽¹⁷⁾. The concept is based on the commonly and widely used BIRADS system for the assessment of focal breast lesions⁽¹⁸⁾. The primary goal of the ACR-TIRADS classification, as well as other ultrasound RSSs, is to identify among TNs those which, based on the ultrasound findings, raise suspicion of neoplastic lesion and thus require deeper diagnostics and additional

procedures, most often using FNAB. Additionally, the classification helps to standardise the conclusions arising from the interpretation of ultrasound images, thus improving and streamlining communication between ultrasound technologists and clinicians, while contributing to a reduction in over-performed FNAB.

ACR-TIRADS, unlike other scales, is based on a unique scoring classification. Of the five categories of ultrasound features, individual elements – morphology, echogenicity, shape, margins, and microcalcifications – are evaluated and assigned a value of 0 to 3 points, with a higher score being associated with a higher risk of malignancy (Tab. 2). The total score determines the TIRADS malignancy risk (TR) divided into the following categories: TR1 – benign (0 point), TR2 – not suspicious (2 points), TR3 – slightly suspicious (3 points), TR4 – moderately suspicious (4–6 points) and TR5 – highly suspicious (≥7 points). The combined assessment of TR grade and maximum lesion diameter determines further management, which may be invasive (FNAB) or observation. The estimated risk of malignancy in each group is: <2% for TR1 and TR2, <5% for TR3, ranging from 5.1% to 20% for TR4 and >20% for TR5. In addition, ACR-TIRADS is part of a new interactive online algorithm, called TNAPP (Thyroid Nodule App), which was presented at the American Association for Clinical Endocrinology annual conference in 2021⁽¹⁹⁾. The innovation of TNAPP is based on combining clinical factors, ultrasound and FNAB features and provide clear suggestions for further management of TNs.

The diagnostic value of ACR-TIRADS has been confirmed in a number of recent studies. In a meta-analysis published by Li et al., including 16 studies and evaluating 21,882 TNs, the authors showed that the meta-analytic overall sensitivity and specificity for risk stratification were 89% (95% CI, 81–93) and 70% (95% CI, 60–78)⁽²⁰⁾. The diagnostic odds ratio (DOR) was 18.46 (95% CI 9.77–34.88). Among these studies, 10/16 articles compared the direct diagnostic utility of ACR with ATA guidelines, while 6 studies compared ACR with Korean TIRADS, observing similar sensitivity (83% vs 87% and 85% vs 91%), but higher specificity of ACR compared with the other two (65% vs 50%, 57% vs 24%).

In conclusion, ACR-TIRADS is a well-established, valuable tool used in the assessment of TN malignancy risk that provides extensive and detailed lesion characterisation with clear management recommendations, thus avoiding unnecessary FNABs. The main disadvantage of this system when used in daily clinical practice is that it is quite time-consuming to use, particularly for novice clinicians.

In 2016, the Korean Society of Thyroid Radiology (KSThR) presented the K-TIRADS classification and recommendations, describing the terminology and symptomatology of ultrasound imaging of focal thyroid lesions⁽²¹⁾. These ultrasound image features were used to develop the K-TIRADS classification and recommendations for each category. In addition to the B-mode image, the authors also detailed the vascularisation types of focal lesions and the potential role of sonoelastography in the differential diagnosis of TNs, but did not include them in the classification itself due to the divergent results presented in the literature. The classification itself is based on the ultrasonographic features of the B-mode image. The following were considered suspicious features: microcalcifications, vertical shape of the lesion, spiculated/microlobulated margins⁽²¹⁾. K-TIRADS 1 corresponds to healthy thyroid parenchyma without focal lesions. K-TIRADS 2 should be assigned to cysts, partially cystic lesions with comet tail artefacts present, and spongiform nodules. Partially cystic lesions that are iso-, hyperechogenic or of mixed echogenicity (iso-/hyper-) without any of the ultrasound suspicious features are assigned to category “3”, while lesions with any of the suspicious features present are assigned to category “4”. Similarly, category 4 is assigned to solid, hypoechogenic lesions without suspicious features. K-TIRADS 5 refers to solid hypoechogenic lesions with at least one suspicious feature present. Further management of focal lesions depends on their size (referring to the largest dimension)⁽²¹⁾:

Compared to ACR-TIRADS, the K-TIRADS classification seems more intuitive, however it should be remembered that ACR-TIR ADS allows (and also requires) a more objective assessment (analysis) of each individual lesion (in contrast to K- and EU-TIRADS). Moreover, it should be noted that focal lesions with suspicious features, with mixed or solid structure and iso-/hyperechogenic in the K-TIRADS classification are in category 4⁽²¹⁾ as in ACR-TIRADS⁽¹⁷⁾classification, whereas in the EU-TIR ADS classification they are assigned to 5⁽⁴⁾. K-TIRADS, like EU-TIRADS, do not consider macro-calcifications, annular calcifications and infiltration beyond the thyroid capsule as higher risk features in contrast to ACR-TIRADS, thus omitting quite important TN features considered suspicious in the literature. Another discrepancy among the classification is seen in the cut-off thresholds for the size of nodules referred for FNAB. The authors of K-TIRADS recommend cytological verification in categories 4 and 5 for lesions measuring ≥10 mm, noting the possibility of selective FNAB in category 5 for lesions >5 mm in size. For EU-TIRADS and ACR-TIRADS category 4, FNAB is recommended if the lesion is >15 mm in size and >10 mm in category 5^(4,17,21). In the meta-analysis by Kim et al., comparing the diagnostic ability of K, ACR-and EU-TIRADS classification against the cut-off points for category 5 (Tab. 3) and 4 or 5 (Tab. 4), no statistically significant differences were found. However, there was a trend towards higher sensitivity values for EU-TIRADS and higher specificity for K-TIRADS, and the sensitivity and specificity results are presented in Tab. 3 and Tab. 4⁽²²⁾. In a second meta-analysis comparing the diagnostic ability of these classifications, a similar conclusion was reached – the results for sensitivity and specificity for these classifications against category 5 (Tab. 5) and 4 or 5 (Tab. 6) are similar⁽²³⁾.

The discussion on the TIRADS classification should also include the problem of fine-needle biopsy and, more specifically, the percentage of unnecessary procedures generated by each classification. This aspect is further discussed in the following meta-analysis⁽²⁴⁾. In this study, the authors indicate that the K-TIRADS classification is characterised by a high percentage of unnecessary biopsies: 55%. The lowest percentage characterises the ACR-TIRADS classification (25%), significantly lower than for K-TIRADS (p <0.05) and lower compared to EU-TIRADS (38%; p = 0 .087). Clearly, t his percentage is closely related to both the stratification of focal lesions (assignment to categories) and the nodule size cut-off point. Thus, borrowing the cut-off points from the ACR-TIRADS

classification and applying them to the K-TIRADS and EU-TIRADS classifications will reduce the proportion of unnecessary FNAB⁽²⁵⁾. However, it is important to note that a reduction in so-called unnecessary biopsies is not necessarily a desirable solution. It may entail an increase in the percentage of undiagnosed tumours, which may negatively affect the survival curve of patients with thyroid cancer. Based on meta-analyses alone, it is difficult to draw a definitive conclusion on the rate of unnecessary biopsies. The economic element, i.e. the percentage of unnecessary biopsies and thus the possible rate of false positives with their consequences that researchers are willing to accept, may be a factor that facilitates the decision.

The aim of this analysis is to evaluate the application of five major classifications: ACR-TIRADS (American College of Radiology guidelines), ATA (American Thyroid Association guidelines), Kwak-TIR ADS, K-TIR ADS (Korean Thyroid Association/Korean Society of Thyroid Radiology (KTA / KSThR) guidelines) (K-TIR ADS is a development of the Kwak-TIRADS classification), and EU-TIRADS (European Thyroid Association (ETA) guidelines) in estimating the malignancy potential of focal thyroid lesions. Over the last few years, a number of studies have been published comparing the use of the TIRADS classification in the assessment of the malignancy risk of focal thyroid lesions, selected elements of which are presented in the following summary.

Yang et al. conducted a meta-analysis of 19 studies evaluating the clinical benefit of using the five classifications enumerated above. The meta-analysis included the results of research presented in articles published between 2015 and 2020. Between 100 and 4,696 focal lesions of the thyroid gland (24,325 lesions in total) diagnosed in between 92 and 4,585 patients were evaluated. All focal thyroid lesions underwent cyto- and/or histopathological evaluation. Twelve of the analysed studies included ACR-TIRADS assessment, 10 – included ATA classification, 6 included Kwak-TIRADS, 4 – EU-TIRADS, and 4 – K-TIRADS. Based on the statistical analysis performed, the high sensitivity of the individual classifications was obtained in the range of 0.84–0.96 (95% CI), while the specificity was presented sequentially for ACR-TIRADS, ATA, Kwak-TIRADS, KTA, and EU-TIRADS, respectively: 0.68, 0.44, 0.62, 0.47, and 0.61 (95% CI) – Tab. 7. An area under the ROC curve (AUC) value >0.8 was obtained for all the classifications, with a distribution of values for the above qualifications amounting to, respectively, 0.8553, 0.8976, 0.9101, 0.9022, and 0.8810, which supports the very good diagnostic accuracy of their use⁽²⁶⁾ (Tab. 7).

In contrast, the head-to-head comparison method yielded relative diagnostic odds ratio RDOR values of 1.57 (ACR vs ATA), 1.37 (ACR vs EU), 1.8 (ACR vs Kwak), 1.74 (ARC vs K), which distinguishes ACR-TIRADS in the analysis (Tab. 8). The authors of the study further highlighted the differences in the TIRADS classification system. ACR and Kwak-TIRADS are based on point classification, whereas the others categorise focal lesions based on sonographic patterns, which in clinical practice seems to be a more intuitive procedure, but associated with lower test accuracy. For example, the EU-TIRADS category 5 or 4 may correspond to ACR-TIRADS TR4/3 or K-TIRADS TR4/3, whereas focal lesions classified as K-TIRADS TR3 and EU-TIRADS category 3 (low risk of malignancy) may be categorised as ACR-TIRADS TR2, meaning no suspicion of malignancy. These differences in eligibility criteria,

which also take into account the size of the lesion, lead to differences in the specificity of the methods used. On the basis of the meta-analysis performed for ACR-TIRADS, the highest diagnostic accuracy in estimating the risk of malignancy and related limitation of indications to perform FNAB were noted⁽²⁶⁾. The authors point out certain limitations of the meta-analysis, including the lack of histopathological verification for each analysed focal lesion. Another limitation of the study was the numerical difference of lesions with malignant potential qualified for the analysis, moreover, there were no sufficient data related to the comparative analysis using K-TIRADS and EU-TIRADS. Also noteworthy is the limitation due to the incompatibility of ultrasound results obtained by different investigators and by the same investigator (inter-observer and intra-observer variability)⁽²⁷⁾. Conclusions from the presented meta-analysis emphasize the clinical usefulness and confirm the validity of recommending the use of TIRADS classification in estimating the malignancy potential of focal thyroid lesions, with an emphasis on the highest accuracy of the method for ACR-TIRADS.

Similar results on the benefits of using the ACR-TIRADS classification were obtained by Castellana et al. who conducted a meta-analysis of 12 studies (six of which were included in the previous meta-analysis) including five classifications (AACE/ACE/AME, ACR-TIR ADS, ATA, EU-TIRADS, and K-TIRADS) to evaluate their use for TN typing for FNAB⁽²⁸⁾. A total of 18,750 TNs were analysed (including 4,378 histopathologically verified malignant lesions and 14,372 cyto- and/or histopathologically verified benign lesions). A DOR value ranging from 2.2 to 4.9 was obtained, with the highest RDOR value in the head-to-head comparative evaluation for ACR-TIRADS vs ATA (p = 0.02) and vs K-TIRADS (p = 0.002), which was due to the highest reliability quotient for a positive result (LR+ (95% CI)). The above results confirm the advantage of using for ACR-TIRADS in evaluating lesions for FNAB and thus reducing the number of unnecessary procedures.

In a subsequent study by Kim et al., a total of 34 studies (analysing a total of 37,585 focal thyroid lesions) were analysed to assess the diagnostic utility of TIRADS in estimating the malignancy risk of focal thyroid lesions by classifying them into TIRADS categories 4 and 5 (TR4, TR5) with three classifiers: EU-TIRADS, ACR-TIRADS, and K-TIRADS⁽²²⁾. For TR5, the highest sensitivity was reported for EU-TIRADS: 78% (95% CI, 64–88%), followed by ACR-TIRADS: 70% (95% CI, 61–79%), and K-TIRADS: 64% (95% CI, 58–70%). The highest specificity for TR5 was observed for K-TIRADS: 93% (95% CI, 91–95%), ACR-TIRADS: 89% (95% CI, 85–92%), and EU-TIRADS: 89% (95% CI, 77–95%). Categorisation up to TR4/5 in all three classifications has a sensitivity of >90%, while the highest specificity was reported for K-TIRADS: 61% (95% CI, 50–72%), though no statistically significant difference was observed between the classifications. However, the results of the meta-analysis indicate a trend towards the highest sensitivity for the use of EU-TIRADS and the highest specificity for K-TIRADS as diagnostic tools in estimating the risk of malignancy associated with focal thyroid lesions.

In a subsequent meta-analysis of 29 papers evaluating a total of 33,748 focal thyroid lesions, Kim et al. reported comparable diagnostic accuracy of the four presented TIRADS classifications in estimating the risk of malignancy. The sensitivity and specificity of the method were considered in relation to ACR-TIRADS, being respectively: 66% and 91% for TR5, and 95% and 55% for TR4/5, K-TIRADS classification: 55% and 95% for TR5, and 89% and 64% for TR4/5, and EU-TIRADS: 82% and 90% for TR5, and 96% and 52% for TR4/5⁽²³⁾. There was no significant advantage for either classification as a prognostic factor for the risk of focal lesion malignancy. Attention was drawn to factors affecting the limitations of the meta-analysis performed; these include differences in the populations studied, inclusion criteria, proportions of patients of either sex, and numbers of malignant lesions analysed.

Kim et al. in their meta-analysis of 8 studies with an analysis of 13,092 focal thyroid lesions reported the lowest rate of unnecessary FNABs compared to ACR-TIRADS classification of 25% (95% CI, 22–29%), statistically significantly lower compared to ATA: 51% (95% CI, 44–58% (p <0.001)) and K-TIRADS: 55% (95% CI, 42–67% (p <0.001 )). In contrast, there was no significant relationship compared with EU-TIRADS: 38% (95% CI, 16–66%, (p = 0.087))⁽²⁴⁾. The above analysis demonstrates the greatest benefit of using the ACR-TIRADS and EU-TIRADS classifications in typing lesions for FNAB, which translates into minimising the number of unnecessary invasive medical procedures.

The presented findings of the meta-analyses prove the diagnostic utility of the TIRADS classification in estimating the risk of malignancy of focal thyroid lesions and confirm the validity of recommending its applications in clinical practice. A head-to-head statistical analysis of the available data provides evidence for the superiority of the ACR-TIRADS classification, which also translates into minimising the number of unnecessary FNAB. However, in order to draw more far-reaching conclusions, it is necessary to conduct more studies using individual TIRADS classifications (including EU-TIRADS, K-TIRADS), taking into account the limitations presented above related to the heterogeneity of the groups subjected to the analysis. An advantage of the EU-TIRADS scale is that it includes only the most important ultrasound features, so its use is not time-consuming, and the scale is easy to apply in clinical practice. The application of the system would facilitate reporting of the thyroid ultrasound result and could improve TN qualification for FNAB.